Pfizer Receives FDA Approval for Retevmo in RET-Mutant Medullary Thyroid Cancer

Pfizer today announced that the FDA has approved Retevmo (selpercatinib) for the treatment of adults and pediatric patients 12 years and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC). In the Phase 1/2 LIBRETTO-001 trial, Retevmo demonstrated an overall response rate of 69% in patients with RET-mutant MTC who had received prior cabozantinib or vandetanib. The median duration of response was 22.0 months. Retevmo is a highly selective RET kinase inhibitor. This approval provides patients with RET-mutant MTC a new targeted treatment option.